PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUE ...